The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells

被引:4
作者
Lee, Kyung-Jun [1 ]
Kim, Nam-Hyeok [1 ]
Kim, Hyeong Su [1 ,2 ]
Kim, Youngmi [1 ]
Lee, Jae-Jun [1 ,3 ]
Kim, Jung Han [2 ]
Cho, Hye-Yon [1 ,4 ]
Jeong, Soo Young [1 ,5 ]
Park, Sung Taek [1 ,5 ]
机构
[1] Hallym Univ, Inst New Frontier Res Team, Chunchon 24252, South Korea
[2] Hallym Univ, Coll Med, Kangnam Sacred Heart Hosp, Dept Internal Med,Med Ctr,Div HematoOncol, Seoul 07441, South Korea
[3] Hallym Univ, Coll Med, Chuncheon Sacred Heart Hosp, Dept Anesthesiol & Pain Med,Med Ctr, Chunchon 24253, South Korea
[4] Hallym Univ, Coll Med,Med Ctr, Dongtan Sacred Heart Hosp, Dept Obstet & Gynecol, Hwaseong 18450, South Korea
[5] Hallym Univ, Med Ctr, Kangnam Sacred Heart Hosp, Dept Obstet & Gynecol,Coll Med, Seoul 07441, South Korea
来源
MEDICINA-LITHUANIA | 2023年 / 59卷 / 05期
关键词
endometrial cancer; ROR1; receptor tyrosine kinase-like orphan receptor; epithelial-mesenchymal transition (EMT); chemoresistance; BETA-CATENIN MUTATION; TYROSINE KINASE ROR1; EXPRESSION; RECEPTOR; ACTIVATION; MANAGEMENT; PATHWAY; ANTIGEN; RISK;
D O I
10.3390/medicina59050994
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Receptor tyrosine kinase-like orphan receptor type 1 (ROR1) plays a critical role in embryogenesis and is overexpressed in many malignant cells. These characteristics allow ROR1 to be a potential new target for cancer treatment. The aim of this study was to investigate the role of ROR1 through in vitro experiments in endometrial cancer cell lines. Materials and Methods: ROR1 expression was identified in endometrial cancer cell lines using Western blot and RT-qPCR. The effects of ROR1 on cell proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) markers were analyzed in two endometrial cancer cell lines (HEC-1 and SNU-539) using either ROR1 silencing or overexpression. Additionally, chemoresistance was examined by identifying MDR1 expression and IC50 level of paclitaxel. Results: The ROR1 protein and mRNA were highly expressed in SNU-539 and HEC-1 cells. High ROR1 expression resulted in a significant increase in cell proliferation, migration, and invasion. It also resulted in a change of EMT markers expression, a decrease in E-cadherin expression, and an increase in Snail expression. Moreover, cells with ROR1 overexpression had a higher IC50 of paclitaxel and significantly increased MDR1 expression. Conclusions: These in vitro experiments showed that ROR1 is responsible for EMT and chemoresistance in endometrial cancer cell lines. Targeting ROR1 can inhibit cancer metastasis and may be a potential treatment method for patients with endometrial cancer who exhibit chemoresistance.
引用
收藏
页数:13
相关论文
共 45 条
  • [1] Mutation of β-catenin gene in endometrial cancer but not in associated hyperplasia
    Ashihara K.
    Saito T.
    Mizumoto H.
    Nishimura M.
    Tanaka R.
    Kudo R.
    [J]. Medical Electron Microscopy, 2002, 35 (1): : 9 - 15
  • [2] ROR1 expression is not a unique marker of CLL
    Barna, Gabor
    Mihalik, Rudolf
    Timar, Botond
    Toemboel, Judit
    Csende, Zsolt
    Sebestyen, Anna
    Boedoer, Csaba
    Csernus, Balazs
    Reiniger, Lilla
    Petak, Istvan
    Matolcsy, Andras
    [J]. HEMATOLOGICAL ONCOLOGY, 2011, 29 (01) : 17 - 21
  • [3] Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
    Baskar, Sivasubramanian
    Kwong, Kayin
    Hofer, Thomas
    Levy, Jessica M.
    Kennedy, Michael G.
    Lee, Elinor
    Staudt, Louis M.
    Wilson, Wyndham H.
    Wiestner, Adrian
    Rader, Christoph
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (02) : 396 - 404
  • [4] EMT in cancer
    Brabletz, Thomas
    Kalluri, Raghu
    Angela Nieto, M.
    Weinberg, Robert A.
    [J]. NATURE REVIEWS CANCER, 2018, 18 (02) : 128 - +
  • [5] Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Bray, Freddie
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Siegel, Rebecca L.
    Torre, Lindsey A.
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2018, 68 (06) : 394 - 424
  • [6] Burke WM, 2014, GYNECOL ONCOL, V134, P393, DOI 10.1016/j.ygyno.2014.06.003
  • [7] Expression of ROR1 has prognostic significance in triple negative breast cancer
    Chien, Hui-Ping
    Ueng, Shir-Hwa
    Chen, Shin-Cheh
    Chang, Yu-Sun
    Lin, Yung-Chang
    Lo, Yun-Feng
    Chang, Hsien-Kun
    Chuang, Wen-Yu
    Huang, Yi-Ting
    Cheung, Yun-Chung
    Shen, Shih-Che
    Hsueh, Chuen
    [J]. VIRCHOWS ARCHIV, 2016, 468 (05) : 589 - 595
  • [8] Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
    Choi, Michael Y.
    Widhopf, George F., II
    Ghia, Emanuela M.
    Kidwell, Reilly L.
    Hasan, Md Kamrul
    Yu, Jian
    Rassenti, Laura Z.
    Chen, Liguang
    Chen, Yun
    Pittman, Emily
    Pu, Minya
    Messer, Karen
    Prussak, Charles E.
    Castro, Januario E.
    Jamieson, Catriona
    Kipps, Thomas J.
    [J]. CELL STEM CELL, 2018, 22 (06) : 951 - +
  • [9] Clements WM, 2002, CANCER RES, V62, P3503
  • [10] ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
    Concin, Nicole
    Matias-Guiu, Xavier
    Vergote, Ignace
    Cibula, David
    Mirza, Mansoor Raza
    Marnitz, Simone
    Ledermann, Jonathan
    Bosse, Tjalling
    Chargari, Cyrus
    Fagotti, Anna
    Fotopoulou, Christina
    Martin, Antonio Gonzalez
    Lax, Sigurd
    Lorusso, Domenica
    Marth, Christian
    Morice, Philippe
    Nout, Remi A.
    O'Donnell, Dearbhaile
    Querleu, Denis
    Raspollini, Maria Rosaria
    Sehouli, Jalid
    Sturdza, Alina
    Taylor, Alexandra
    Westermann, Anneke
    Wimberger, Pauline
    Colombo, Nicoletta
    Planchamp, Francois
    Creutzberg, Carien L.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 154 : 327 - 353